S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$56.91
+0.88 (+1.57 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$55.00
Now: $56.91
$56.93
50-Day Range
$48.47
MA: $53.35
$56.47
52-Week Range
$20.47
Now: $56.91
$57.07
Volume909,595 shs
Average Volume1.43 million shs
Market Capitalization$6.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.79
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

347th out of 1,922 stocks

Testing Laboratories Industry

1st out of 3 stocks

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600
Employees1,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.83 million
Cash Flow$0.56 per share
Book Value$4.86 per share

Profitability

Net Income$8.01 million

Miscellaneous

Market Cap$6.32 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$56.91
+0.88 (+1.57 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

How has NeoGenomics' stock price been impacted by COVID-19 (Coronavirus)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 129.7% and is now trading at $56.91.
View which stocks have been most impacted by COVID-19
.

Is NeoGenomics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NeoGenomics?

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NeoGenomics
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, October, 27th. The medical research company reported $0.06 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.02. The medical research company had revenue of $125.40 million for the quarter, compared to analysts' expectations of $126.23 million. NeoGenomics had a negative net margin of 1.16% and a positive trailing twelve-month return on equity of 0.71%. The firm's revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business earned $0.07 earnings per share.
View NeoGenomics' earnings history
.

How often does NeoGenomics pay dividends? What is the dividend yield for NeoGenomics?

NeoGenomics declared a dividend on Tuesday, December 15th. Investors of record on Friday, December 18th will be paid a dividend of $0.40 per share on Wednesday, December 30th. This represents a yield of 3.13%. The ex-dividend date of this dividend is Thursday, December 17th.
View NeoGenomics' dividend history
.

What price target have analysts set for NEO?

11 equities research analysts have issued 1 year price targets for NeoGenomics' stock. Their forecasts range from $14.50 to $60.00. On average, they expect NeoGenomics' share price to reach $41.86 in the next twelve months. This suggests that the stock has a possible downside of 26.4%.
View analysts' price targets for NeoGenomics
or view Wall Street analyst' top-rated stocks.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 65, Pay $1.57M)
  • Ms. Kathryn B. McKenzie, Chief Financial Officer (Age 36, Pay $400k)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 58, Pay $645k)
  • Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 49, Pay $683k)
  • Dr. Lawrence M. Weiss M.D., Chief Medical Officer (Age 63, Pay $860k)
  • Mr. Steven A. Ross, VP & Chief Information Officer (Age 56)
  • Charlie Eidson, Mang. of Investor Relations and Strategy & Corp. Devel.
  • Ms. Denise E. Pedulla, Gen. Counsel & Corp. Sec. (Age 60)
  • Ms. Stephanie K. Bywater, Chief Compliance Officer (Age 49)
  • Mr. Douglas M. Brown, Chief Strategy & Corp. Devel. Officer (Age 50)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.27%), Scout Investments Inc. (0.20%), Summit Creek Advisors LLC (0.16%), New York State Teachers Retirement System (0.15%), Strs Ohio (0.14%) and State of Alaska Department of Revenue (0.08%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, State of Alaska Department of Revenue, Summit Creek Advisors LLC, and New York State Teachers Retirement System. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Exchange Traded Concepts LLC, Nisa Investment Advisors LLC, Kestra Advisory Services LLC, Scout Investments Inc., Janney Montgomery Scott LLC, Calton & Associates Inc., and Welch & Forbes LLC.
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $56.91.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $6.32 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.